Human Genome Found to Encode Previously Unknown Category of Molecule

For decades, biology textbooks taught that only two types of large molecules — proteins and lipids — could be decorated with sugar chains (glycans) and displayed on the surface of living cells. In 2021, a team at Stanford University proposed that RNA could do the same thing. In August 2024, after years of skepticism and painstaking chemistry, they proved it [1][2].

The molecule is called glycoRNA: a small noncoding RNA covalently bonded to complex sugar structures. Its confirmed existence expands the catalog of known glycoconjugates from two classes to three, and it places RNA — traditionally confined to the cell interior — squarely on the cell surface, where it can participate in communication between cells [3].

The Discovery: From Accident to "Bombshell"

The glycoRNA story begins with Ryan Flynn, then a postdoctoral researcher in Nobel laureate Carolyn Bertozzi's lab at Stanford. Using bioorthogonal chemistry — a technique Bertozzi pioneered that allows researchers to label specific molecules inside living cells without disrupting normal biology — Flynn attached chemical tags to glycans (sugar molecules) to track their location [4].

What he found was unexpected: the glycan labels kept showing up on RNA. "We thought it was contamination at first," Flynn later recalled. But repeated experiments across human, mouse, hamster, and zebrafish cells showed the same pattern [3][4].

The initial 2021 paper in Cell described "small RNAs modified with N-glycans and displayed on the surface of living cells." The RNAs in question were primarily Y RNAs and small nuclear RNAs — types of noncoding RNA whose functions remain only partly understood [5]. The glycans attached to them were sialylated N-glycans, the same complex sugar structures found on glycoproteins.

Proving the Chemical Bond

The 2021 findings drew immediate scrutiny. Critics pointed out that the data were "consistent with" glycoRNA existing but did not demonstrate a direct chemical bond between RNA and sugar. Glycoproteins and RNA could simply be co-purifying — sticking together during lab extraction without being genuinely linked [6][7].

Flynn, who established his own lab at Boston Children's Hospital and Harvard's Department of Stem Cell and Regenerative Biology, spent nearly four years developing the proof. In August 2024, his team published definitive evidence in Cell: using a combination of chemical labeling (RNA-optimized periodate oxidation and aldehyde ligation, or rPAL) and sequential window acquisition of all theoretical mass spectra (SWATH-MS), they identified the specific attachment site [1][2].

The linkage occurs at a modified RNA base called 3-(3-amino-3-carboxypropyl)uridine (acp3U). This base, found on transfer RNAs, undergoes conversion to a carboxamide form, enters the endoplasmic reticulum lumen, and becomes N-glycosylated through the same enzymatic pathway that glycosylates proteins. The resulting glycoRNA then traffics through the secretory pathway to the cell surface [1][2].

Where GlycoRNA Fits Among Known Biomolecules

The five traditionally recognized classes of biological macromolecules are DNA, RNA, proteins, lipids, and carbohydrates. GlycoRNA does not constitute a sixth class in this taxonomy — it is RNA bearing glycan modifications, analogous to how glycoproteins are proteins bearing glycan modifications [3][8].

What makes glycoRNA categorically significant is that glycoconjugates — molecules that display glycans — were previously limited to proteins and lipids. RNA was not thought to enter the secretory pathway at all, let alone emerge on the outer face of cells decorated with sugars. The discovery means that the "glycome" (the totality of sugars on a cell's surface) is more diverse than previously understood, requiring updated models of how cells present molecular identity to their neighbors [3][8].

GlycoRNA shares structural motifs with both its parent classes: it retains the nucleotide backbone of RNA while displaying the branched sugar structures of N-linked glycans. No entirely new biochemical framework is needed, but existing frameworks for glycobiology and RNA biology must now be integrated in ways researchers had not anticipated [8].

The Genomic Landscape

The RNAs that form glycoRNAs are encoded by well-characterized genomic loci. Y RNAs, which constitute a major fraction of identified glycoRNAs, are encoded by four functional genes in humans (RNY1, RNY3, RNY4, RNY5), while the transfer RNAs bearing acp3U modifications are distributed across approximately 500 tRNA genes scattered throughout the genome [5][9].

These sequences were not previously classified as "junk DNA" — they are known noncoding RNA genes. However, the discovery that their RNA products undergo glycosylation and traffic to the cell surface represents an entirely new function for these sequences. The broader question of whether additional noncoding RNAs beyond Y RNAs and tRNAs can be glycosylated remains open. The GlycoRNAdb, published in January 2026, catalogues glycoRNA sequences, structures, and glycan composition across human and mouse tissues and cell lines, providing the first systematic inventory [9].

Evolutionary Conservation

One of the strongest arguments for glycoRNA's biological importance is its conservation across species. Flynn's team identified glycoRNAs in human, mouse, hamster, and zebrafish cells [3][4]. Given that zebrafish and mammals diverged approximately 450 million years ago, the presence of glycoRNAs in both lineages suggests the modification arose early in vertebrate evolution — or possibly earlier.

A 2022 report in New Atlas noted that the structural similarity of glycoRNAs across such distantly related species "suggests glycoRNAs could have ancient origins and may have had some role in the emergence of life on Earth" [10]. Whether this represents deep conservation of an ancestral function or independent co-option of the same chemistry remains unresolved.

Disease Connections: Autoimmunity and Beyond

The immune implications emerged quickly. GlycoRNAs carry sialic acid caps — the same sugar residues recognized by Siglec receptors on immune cells. Siglecs function as immune checkpoints: when they detect sialic acid on a cell surface, they signal the immune system to stand down [3][4].

Flynn's team showed that glycoRNAs interact with Siglecs, raising a hypothesis: could defects in glycoRNA display cause the immune system to mistakenly attack the body's own tissues? The RNAs that compose glycoRNAs — particularly Y RNAs — have long been known as targets of autoantibodies in patients with systemic lupus erythematosus (SLE) [3][11].

A 2025 study in Scientific Reports identified glycosylation-related differentially expressed genes as diagnostic biomarkers in SLE, with genes such as RNASE2, CXCL2, and LAMP3 significantly elevated in patient cohorts compared to healthy controls [11]. However, these studies have not yet directly measured glycoRNA levels in patient samples, and the cohort sizes in existing glycosylation-SLE studies typically range from dozens to low hundreds of patients.

Emerging research also points to cancer. A 2025 review in Discover Oncology described glycoRNA as "a novel RNA modification" with potential roles in tumor biology, though mechanistic studies remain in early stages [12].

Source: OpenAlex

Data as of Jan 1, 2026CSV

The Skeptics' Case

Not all scientists accept that "new category of molecule" is the right framing. A 2025 paper in Experimental & Molecular Medicine demonstrated that glycoproteins — particularly LAMP1 — copurify with RNA during extraction procedures, meaning some signals attributed to glycoRNA may actually reflect protein contamination [6].

The study concluded that "glycoproteins can mimic glycoRNA owing to their similar properties, potentially complicating research." This does not disprove glycoRNA's existence — the 2024 Cell paper addressed this concern with direct chemical evidence — but it highlights how easily results can be confounded [6][1].

A 2025 review in Protein & Cell titled "GlycoRNA research: from unknown unknowns to known unknowns" acknowledged persistent challenges: "the inherent bias of current detection methods, the difficulty of isolating pure glycoRNA samples from complex cellular mixtures, and the largely unknown mechanisms of specific glycan linkages" [7].

Some researchers argue that glycoRNA is better understood as a post-transcriptional modification of known RNA species — analogous to how methylation modifies DNA without creating a "new category" of nucleic acid. Under this view, calling glycoRNA a new biomolecular category overstates what is essentially a biochemical decoration of existing molecules. The counterargument, advanced by Flynn and others, is that glycosylation fundamentally changes what RNA does: it relocates RNA to the cell surface and gives it an immune-signaling function that unmodified RNA cannot perform [1][3].

The Path to Clinical Applications

How quickly could glycoRNA research yield diagnostics or therapeutics? History suggests patience is warranted.

Source: PMC / FDA Records

Data as of Dec 1, 2024CSV

MicroRNAs were discovered in 1993. More than 30 years later, no miRNA-based therapy has received FDA approval, though several have entered clinical trials [13]. Small interfering RNA (siRNA) took 20 years from discovery to the approval of Onpattro in 2018. CRISPR-Cas9, described in 2012, reached its first FDA approval (Casgevy for sickle cell disease) in December 2023 — an 11-year timeline considered remarkably fast [14][15].

GlycoRNA, with its definitive chemical proof published only in 2024, is at the earliest possible stage of translational research. No clinical trials involving glycoRNA are registered. The most plausible near-term applications are diagnostic rather than therapeutic: if glycoRNA display on cell surfaces correlates with autoimmune disease activity, measuring glycoRNA levels in patient blood could serve as a biomarker [3].

Any therapeutic targeting glycoRNA would likely proceed through the FDA's biological product pathway (BLA), potentially with breakthrough therapy designation if early clinical data show substantial improvement over existing treatments for conditions like lupus. A realistic timeline for first-in-human studies, based on historical precedent, is 8-15 years from now [13][14].

The Intellectual Property and Funding Landscape

Stanford University filed patents on glycoRNA-related technology around the time of the 2021 discovery, given the institution's standard practice of patent protection for faculty inventions. The University of Texas has licensed ARPLA (a glycoRNA imaging tool) through its Office of Technology Commercialization [16].

Flynn's lab at Boston Children's Hospital / Harvard has become the primary academic center for glycoRNA research, with active collaborations with immunologists and rheumatologists [4]. No dedicated biotech company focused exclusively on glycoRNA therapeutics has been publicly announced as of early 2026, though the broader glycobiology space has attracted significant venture investment.

The National Institutes of Health funds glycoRNA research through existing mechanisms (R01 grants, center grants) rather than a dedicated program. The field remains too young for the large-scale targeted funding that CRISPR or the Human Genome Project attracted [9].

Source: OpenAlex

Data as of Jan 1, 2026CSV

What Comes Next

The glycoRNA field faces several immediate questions. First, researchers need to determine the full repertoire of RNAs that can be glycosylated — are Y RNAs and tRNAs the only substrates, or is this a broader phenomenon? Second, the enzymes responsible for RNA glycosylation in the endoplasmic reticulum need to be identified. Third, functional studies must establish what happens when glycoRNA is removed from cell surfaces — does the immune system activate, as the Siglec hypothesis predicts?

The publication rate tells a story of rapid growth: from just 2 papers in 2019 to 123 in 2025, with 324 total papers now in the literature [9]. The broader field of noncoding RNA glycosylation has produced over 6,700 papers, though most predate the glycoRNA concept [9].

Whether glycoRNA ultimately proves to be a footnote in RNA biology or a fundamental pillar of cell surface biology depends on answers to questions that are, for now, still being formulated. The molecule is real. The chemistry is proven. The biology remains wide open.